Issues
-
Cover Image
Cover Image
FAK is a ubiquitously expressed nonreceptor tyrosine kinase that regulates several endothelial cell processes important for angiogenesis, including motility and proliferation. This work describes the differential roles of endothelial cell FAK phosphorylation at tyrosines-397 and -861 for tumor angiogenesis in vivo. Using immunofluorescence, the authors found that different nonphosphorylatable tyrosine mutations within endothelial cell FAK, namely Y397 and Y861, have different binding abilities to phosphorylated Src. While loss of FAK-Y397 phosphorylation impairs binding of FAK to p-Src, loss of FAK-Y861 phosphorylation does not affect binding to p-Src at focal adhesion sites as shown in this image. For details see article by Pedrosa and colleagues on page 4371. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Reviews
Cancer Research Highlights
Controversy and Consensus
Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma
Priority Report
Genome and Epigenome
Molecular Cell Biology
Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells
Tumor Angiogenesis Is Differentially Regulated by Phosphorylation of Endothelial Cell Focal Adhesion Kinase Tyrosines-397 and -861
Tumor Biology and Immunology
CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Translational Science
Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer
Convergence and Technologies
Population and Prevention Science
Resource Report
Corrections
Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer
Retraction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.